difference between semaglutide and peptides A new era for oral peptides: SNAC the development of oral for the treatment of type 2 diabetes | Reviews in Endocrine and Metabolic Disorders Semaglutide vs Tirzepatide, Cagrilintide, and

The Path Forward: Balancing Innovation, Safety, and Access The ongoing legal battles surrounding GLP-1 agonists serve as a microcosm of the broader challenges in the pharmaceutical landscape

Sergey Terushkin, MD, FACS Dr

Platelet oxidative stress and systemic inflammation in chronic spontaneous urticaria

#PharmaNews #PharmaResults #EarningsUpdate #IndianPharma #PharmaUpdates #Harshal #PharmawithHJ #HJ Gland Pharma FY25 Results: Strong Margins, 31 Product Launches Gland Pharma Limited FY25 Results: Margins Hold Strong, Strategy Gathers Steam Financial Highlights: - FY25 Revenue: 5,617 Cr (1% YoY) - EBITDA Margin: 1,269 Cr (5% YoY) | Margin 23% - PAT: 698 Cr (10% YoY) | Margin at 12% - Dividend: 18/share final dividend recommended Business Highlights: - 31 product launches in FY25, including new molecules like Latanoprost & Dexamethasone - 32 ANDA approvals, 24 filings U.S

Skyrizi for psoriatic arthritis In the KEEPsAKE-1 clinical trial (NCT03675308), 56.3% of adults using Skyrizi had at least a 20% improvement in joint pain, tenderness, and other measures of disease activity (ACR20 response) after 16 weeks, compared to 33.4% with placebo